Chimeric orthopoxvirus
WebAug 15, 2024 · Introduction and Objective: CF33-hNIS is a novel, chimeric orthopoxvirus with robust anti-tumor activity at relatively low titers and with a low multiple of infectivity (MOI) in a variety of pre-clinical models. This is a Phase 1, open-label, dose escalation study in adult patients with selected advanced or metastatic solid tumors to evaluate the safety … WebNational Center for Biotechnology Information
Chimeric orthopoxvirus
Did you know?
WebApr 28, 2024 · One hundred chimeric orthopoxvirus plaques were picked from CV-1 cells infected with the chimeric orthopoxvirus pool. These 100 plaques were further plaque purified two more times in CV-1 cells to … WebFeb 4, 2024 · CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). The in vitro cytotoxic ability of this virus against five PDAC cell lines was tested at various doses (multiplicity of infection (MOI) = 0.01, 0.1, 1, 10). Production and …
WebOct 9, 2024 · The conditionally replication-competent chimeric orthopoxvirus (CF17) successfully exhibited the ability to suppress tumor growth and increase survival in preclinical peritoneal ovarian metastases … WebSep 25, 2024 · One such OV is CF33, a chimeric poxvirus created by chimerization of nine species of orthopoxvirus, including multiple strains of vaccinia virus selected for enhanced anti-tumor activity. 23, 24, 25 CF33 has a mutation in the J2R (thymidine kinase [TK]) gene, and hence it depends on the cellular pool of thymidine triphosphate.
WebFeb 1, 2024 · CF33-hNIS-antiPDL1, a chimeric orthopoxvirus expressing the human sodium iodide symporter (hNIS) and anti-human programmed death-ligand 1 antibody, has demonstrated robust preclinical activity ... WebNational Center for Biotechnology Information
WebScientific Abstract: Oncolytic virotherapy represents a promising approach for treating recurrent and/or drug-resistant ovarian cancer. However, its successful application in the …
WebJul 6, 2024 · One such OV is CF33, a chimeric poxvirus created by chimerization of nine species of orthopoxvirus, including multiple strains of vaccinia virus selected for enhanced anti-tumor activity. 23 O’Leary M.P. cif bid deadline 2022WebFor these studies, we used an oncolytic chimeric orthopoxvirus, de-signed to infect a large spectrum of tumors (13–17), carrying CD19t under the control of the vaccinia synthetic early promoter (P SE; Fig. 1A). This construction enables rapid expression of CD19t and appearance of the protein at the cell surface before oncolytic viral- dharani survey no checkingWebCF33-hNIS-antiPDL1, a chimeric orthopoxvirus expressing the human sodium iodide symporter (hNIS) and anti-human programmed death-ligand 1 antibody, has demonstrated robust preclinical activity ... dharani westborough buffet priceWebJun 2, 2024 · CF33-hNIS-anti-PD-L1 (CHECKvacc) is a novel chimeric orthopoxvirus with robust anti-cancer activity in TNBC xenografts. Cells infected with CHECKvacc were shown to express functional human sodium-iodide symporter (hNIS) and anti-PD-L1 proteins. hNIS gene transfer allows tracking of virus by 99mTc single-photon emission computed … cif bid resultsWebSep 25, 2024 · Anthony K. Park et.al utilized an oncolytic chimeric orthopoxvirus carrying a CD19t-encoding gene to infect solid tumor cells including those of pancreatic cancer, prostate cancer, and breast cancer. They demonstrated that OVs can effectively deliver the CD19-CAR target to solid tumors and upregulate the expression of CD19t on the surface … cif billingham european giftsWebJun 29, 2024 · One hundred chimeric orthopoxvirus plaques were picked from CV-1 cells infected with the chimeric orthopoxvirus pool. These 100 plaques were further plaque purified two more times in CV-1 cells to yield 100 clonally purified individual chimeric virus isolates, which, together with the parental viruses, were subjected to high-throughput ... dharani westborough macif bids 2023